Literature DB >> 23246432

Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity.

Bénédicte F Py1, Mi-Sung Kim, Helin Vakifahmetoglu-Norberg, Junying Yuan.   

Abstract

NLRP3 is an important pattern recognition receptor involved in mediating inflammasome activation in response to viral and bacterial infections as well as various proinflammatory stimuli associated with tissue damage or malfunction. Upon activation, NLRP3 assembles a multimeric inflammasome complex comprising the adaptor ASC and the effector pro-caspase-1 to mediate the activation of caspase-1. Although NLRP3 expression is induced by the NF-κB pathway, the posttranscriptional molecular mechanism controlling the activation of NLRP3 remains elusive. Using both pharmacological and molecular approaches, we show that the activation of NLRP3 inflammasome is regulated by a deubiquitination mechanism. We further identify the deubiquitinating enzyme, BRCC3, as a critical regulator of NLRP3 activity by promoting its deubiquitination and characterizing NLRP3 as a substrate for the cytosolic BRCC3-containing BRISC complex. Our results elucidate a regulatory mechanism involving BRCC3-dependent NLRP3 regulation and highlight NLRP3 ubiquitination as a potential therapeutic target for inflammatory diseases.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23246432     DOI: 10.1016/j.molcel.2012.11.009

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  253 in total

1.  Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease.

Authors:  Xiaojuan Han; Sifan Sun; Yiming Sun; Qiqi Song; Jialei Zhu; Nanshan Song; Miaomiao Chen; Ting Sun; Meiling Xia; Jianhua Ding; Ming Lu; Honghong Yao; Gang Hu
Journal:  Autophagy       Date:  2019-04-09       Impact factor: 16.016

2.  PLK4 deubiquitination by Spata2-CYLD suppresses NEK7-mediated NLRP3 inflammasome activation at the centrosome.

Authors:  Xiao-Dong Yang; Wenguo Li; Shuangyan Zhang; Dandan Wu; Xiaoli Jiang; Rong Tan; Xiaoyin Niu; Qijun Wang; Xuefeng Wu; Zhiduo Liu; Lin-Feng Chen; Jun Qin; Bing Su
Journal:  EMBO J       Date:  2019-11-25       Impact factor: 11.598

Review 3.  Regulation of inflammasome activation.

Authors:  Si Ming Man; Thirumala-Devi Kanneganti
Journal:  Immunol Rev       Date:  2015-05       Impact factor: 12.988

Review 4.  Initiation and perpetuation of NLRP3 inflammasome activation and assembly.

Authors:  Eric I Elliott; Fayyaz S Sutterwala
Journal:  Immunol Rev       Date:  2015-05       Impact factor: 12.988

Review 5.  Inflammasomes and intestinal inflammation.

Authors:  N Zmora; M Levy; M Pevsner-Fishcer; E Elinav
Journal:  Mucosal Immunol       Date:  2017-04-12       Impact factor: 7.313

6.  The NLRP3 inflammasome activation in human or mouse cells, sensitivity causes puzzle.

Authors:  Hongbin Wang; Liming Mao; Guangxun Meng
Journal:  Protein Cell       Date:  2013-08       Impact factor: 14.870

Review 7.  Mechanism and Regulation of NLRP3 Inflammasome Activation.

Authors:  Yuan He; Hideki Hara; Gabriel Núñez
Journal:  Trends Biochem Sci       Date:  2016-09-23       Impact factor: 13.807

8.  K+ efflux agonists induce NLRP3 inflammasome activation independently of Ca2+ signaling.

Authors:  Michael A Katsnelson; L Graham Rucker; Hana M Russo; George R Dubyak
Journal:  J Immunol       Date:  2015-03-11       Impact factor: 5.422

9.  The mitochondrial antiviral protein MAVS associates with NLRP3 and regulates its inflammasome activity.

Authors:  Sangjun Park; Christine Juliana; Sujeong Hong; Pinaki Datta; Inhwa Hwang; Teresa Fernandes-Alnemri; Je-Wook Yu; Emad S Alnemri
Journal:  J Immunol       Date:  2013-09-18       Impact factor: 5.422

10.  NLRP3 inflammasome in NMDA-induced retinal excitotoxicity.

Authors:  Pavlina Tsoka; Paulo R Barbisan; Keiko Kataoka; Xiaohong Nancy Chen; Bo Tian; Peggy Bouzika; Joan W Miller; Eleftherios I Paschalis; Demetrios G Vavvas
Journal:  Exp Eye Res       Date:  2019-01-29       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.